Brigham Health physician leaders shared their perspectives on building a healthier world through international partnerships during the C3 China-U.S. Healthcare Summit in Beijing, held March 29–30. Bringing together hundreds of international experts in health care and academia, the inaugural summit advanced the transfer of knowledge and best practices in health care to China as the country undergoes significant changes in health care delivery.
Invited to lead a keynote panel, Mark Davis, MD, MS, vice president of Brigham Health International and executive director of the Brigham’s Business Development and Strategic Initiatives group, discussed the deepening collaboration in international health care and the China-U.S. partnership, and moderated a panel discussion on this topic. Jeffrey Golden, MD, chair of the Department of Pathology, spoke about the role of artificial intelligence in cancer diagnosis, and Giles Boland, MD, chair of the Department of Radiology, addressed the promise of digital radiology and telemedicine in improving patient care globally. Telemedicine uses the internet and other technologies to transmit digital images to a physician who can provide a diagnosis or second opinion from a different location.
Through their participation in meetings and summit panels, including those centered on improving cancer care in China and implementing telemedicine, the Brigham cohort shared their expertise on how academic medical centers can partner with China’s growing health care system around clinical care, education and research. According to Davis, telemedicine is an increasingly important aspect of current collaborations between the Brigham and Chinese institutions.
“Through international collaboration and innovation, we can fulfill the Brigham’s mission to serve the needs of our global as well as our local community and address complex health care challenges in China and beyond,” said Davis, whose presentation covered the Brigham’s experiences over the last few years in establishing relationships with both private and public partners in China.